Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 6/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 2/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784683 | 0.96 | BACE1 (0.41) | HDAC2HDAC1HDAC3BACE1QDPR | |
| SCHEMBL3791189 | 0.95 | BACE1 (0.44) | HDAC2HDAC1HDAC3BACE1QDPR | |
| SCHEMBL3788024 | 0.93 | HDAC1 (0.41) | HDAC2HDAC1HDAC3BACE1QDPR | |
| SCHEMBL3791507 | 0.86 | HDAC1 (0.42) | HDAC2HDAC1HDAC3BACE1QDPR | |
| SCHEMBL3784952 | 0.84 | QDPR (0.39) | HDAC2QDPRACMSDESR2HDAC4 | |
| SCHEMBL3786600 | 0.82 | HDAC1 (0.42) | HDAC2HDAC1HDAC3BACE1QDPR | |
| SCHEMBL3782197 | 0.81 | BACE1 (0.44) | HDAC2HDAC1HDAC3BACE1QDPR | |
| SCHEMBL3791565 | 0.80 | QDPR (0.39) | HDAC2QDPRACMSDESR2HDAC4 | |
| SCHEMBL3783960 | 0.80 | ACMSD (0.41) | HDAC2HDAC1BACE1QDPRACMSD | |
| SCHEMBL3785181 | 0.79 | ACMSD (0.42) | HDAC2HDAC1BACE1QDPRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | HDAC2 549/4885HDAC1 1686/4885HDAC3 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.